At a glance
| Field | Details |
|---|---|
| Brand names | Victoza (T2D), Saxenda (obesity) |
| Targets | GLP-1R |
| Developer | Novo Nordisk |
| Modality | SC injection, once-daily |
| Approval status | Approved — US (Victoza 2010, Saxenda 2014) |
| Key efficacy | ~8% weight loss at 56 weeks (Saxenda 3mg, SCALE trial) |
| Indications | Type 2 diabetes, obesity, cardiovascular risk reduction |
User Sentiment
Patients who've been on Saxenda longest are often the ones who switched to it before Wegovy was available — and many report it worked well, just with more daily friction. The once-daily injection is the most consistent complaint. Results are real but more gradual than weekly drugs.
Example(What the community says)
Common thread on Saxenda forums: the nausea hits faster and harder with daily dosing than with weekly drugs (higher peak drug levels each day). People who stuck through the first month generally report it settled. Those who quit usually did so in weeks 2–3 when the GI side effects peaked.
How it works
A GLP-1 analog with a C16 fatty acid chain extending half-life to ~13 hours — long enough for once-daily dosing but not weekly. The same albumin-binding mechanism as semaglutide with a shorter chain, resulting in lower peak exposure and a lower efficacy ceiling. Activated GLP-1R drives the same downstream effects as all single agonists: appetite suppression, insulin secretion, glucagon suppression, gastric slowing.
Note(Once-daily vs once-weekly: the adherence gap)
The main clinical disadvantage vs semaglutide isn't efficacy — it's injection frequency. 365 injections per year vs 52. Across a multi-year obesity treatment course that difference is significant. In practice, patients who choose liraglutide over weekly alternatives usually do so for cost or formulary reasons, not preference.
Trial data
SCALE Obesity (Saxenda 3mg, 56 weeks): ~8% mean weight loss. ~63% of participants lost at least 5% of body weight, ~33% lost at least 10%.
LEADER trial (Victoza, T2D, cardiovascular outcomes): ~13% reduction in MACE in patients with high cardiovascular risk — the first GLP-1 drug to demonstrate cardiovascular benefit, establishing the precedent that semaglutide later built on with SELECT.
What to Expect
Weeks 1–2 — Nausea tends to be more pronounced than weekly alternatives because daily injections create higher daily peaks. Eating small, low-fat meals helps.
Month 1–2 — Appetite reduction kicks in. 3–5% weight loss typical.
Month 3–6 — Steady but modest progress. The ~8% average weight loss from SCALE took 56 weeks — this is a slower curve than semaglutide.
Ongoing — Daily injection routine. People who find a consistent time (usually morning) report better adherence than those who inject at variable times.
Dosing and administration
0.6mg/day for one week → 1.2mg → 1.8mg → 2.4mg → 3mg/day maintenance over 5 weeks. Daily injection is the primary practical disadvantage vs semaglutide. Available in a multi-dose pen with dose dial.
Development status
| Milestone | Status |
|---|---|
| Victoza (T2D) | Approved US 2010 |
| Saxenda (obesity) | Approved US 2014 |
| Saxenda pediatric (≥12 years) | Approved 2020 |
| Market position | Declining as semaglutide captures formularies |
Safety profile
GI profile similar to semaglutide — nausea, vomiting, diarrhea most common during titration, self-limiting. Same thyroid C-cell black box warning. Daily injection increases injection site burden vs weekly drugs. Higher discontinuation rates than once-weekly alternatives in head-to-head adherence studies.
Who It's For
- BMI ≥ 30, or ≥ 27 with a weight-related condition
- Patients in markets where Wegovy access or coverage is limited
- People who've already tried semaglutide and want an alternative formulation
- Adolescents 12+ with obesity — Saxenda has pediatric approval that Wegovy doesn't have everywhere
Ask a provider whether liraglutide or a weekly alternative is the right starting point for your situation.
Summary(The liraglutide picture)
The class's first cardiovascular outcome data (LEADER), now largely superseded by weekly drugs on efficacy and adherence. Still relevant where Wegovy isn't covered or in markets where semaglutide access lags. The daily injection burden is the primary practical limitation.